S&P Futures
3,884.00-14.75(-0.38%)Dow Futures
31,394.00-115.00(-0.36%)Nasdaq Futures
13,247.25-32.50(-0.24%)
Precipio, Inc. (PRPO)
2.6500 +0.04 (1.53%)
After hours: 7:20PM EST
Chart Events
Performance Outlook
| Previous Close | 2.4400 |
| Open | 2.4600 |
| Bid | 2.6200 x 800 |
| Ask | 2.6100 x 900 |
| Day's Range | 2.4600 - 2.6302 |
| 52 Week Range | 0.5500 - 8.0000 |
| Volume | 217,403 |
| Avg. Volume | 1,033,008 |
| Market Cap | 44.962M |
| Beta (5Y Monthly) | 2.88 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.4690 |
| Earnings Date | Mar 25, 2021 - Mar 29, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Related Research
- GlobeNewswire
Precipio Launches COVID-19 Antibody Testing at Point-of-Care
Following the receipt of FDA EUA by Nirmidas, Precipio begins market roll out to POCNEW HAVEN, Conn., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces that following receipt of an Emergency Use Authorization from the FDA by Nirmidas Biotech, Inc., the developer and manufacturer of the COVID-19 antibody test, Precipio has begun to roll out these tests to the market. After signing a sales and distribution agreement with Nirmidas earlier this week, Precipio has started with its installed oncology customer base, and will continue to expand into the market via additional sales channels. The test, produced by Nirmidas, a biotech company based in Palo Alto, CA is the first US-based product to receive EUA for point-of-care for its rapid COVID-19 antibody test. As the nationwide rollout of the vaccine continues, the value of rapid antibody testing increases dramatically. First, to those who are deliberating whether to take the vaccine or not, the results of an antibody testing offers another important data point in making that decision. Individuals who have been infected with the virus (whether they display symptoms, or are asymptomatic), and subsequently develop antibodies that are detected by the COVID-19 antibody test, can use that result as another decision-making factor as they consider the vaccine. The test offered by Precipio employs the SARS-CoV-2 spike protein’s RBD antigen for detection, which is the specific binding target of neutralization antibodies resulting from vaccines or prior COVID-19 infection. Additionally, given that the vaccine is designed to create a response that will cause the body to develop antibodies, the ability to test for the presence of these antibodies post-vaccination will provide an important tool for individuals and healthcare providers to assess the efficacy of the vaccine. Precipio encourages all individuals to consult with their physician as to their decisions regarding testing, vaccination, and other decisions regarding their healthcare. “We are excited to partner with Precipio to make our tests rapidly and widely deployed in the US for point-of-care testing,” said Nirmidas CEO Dr. Meijie Tang. “We also look forward to developing a test that could be used in every household.“ “We are delighted to see the fruits of our work culminate in the ability to now bring this important test to the market, and contribute to the battle against this pandemic,” said Ilan Danieli, Precipio’s CEO. “The FDA continues to demonstrate their willingness to expand the reach and usability of these tests, and we hope to soon see progress on the at-home testing front as well.” About Nirmidas Based in Silicon Valley, Nirmidas combines chemistry, biology, bio-engineering, and optical imaging, with a focus on red to near-infrared fluorescence enhancement technologies. Commercialized applications include diagnostics and imaging for early disease diagnosis, prognosis monitoring, population screening, and therapeutics. Nirmidas was originally a spin-off from Stanford University and is a member of the StarX Med COVID-19 Task Force. Please visit www.nirmidas.com. About Precipio Precipio has built a platform designed to eradicate the problem of misdiagnosis by harnessing the intellect, expertise and technology developed within academic institutions and delivering quality diagnostic information to physicians and their patients worldwide. Through its collaborations with world-class academic institutions specializing in cancer research, diagnostics and treatment such as the Yale School of Medicine, Harvard’s Dana-Farber Cancer Institute, and the University of Pennsylvania, Precipio offers a new standard of diagnostic accuracy enabling the highest level of patient care. For more information, please visit www.precipiodx.com. Please follow us on Twitter @PrecipioDx and on Facebook. Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, among others, statements related to the expected or potential impact of the novel coronavirus (COVID-19) pandemic, and the related responses of the government, consumers, and the company, on our business, financial condition and results of operations, and any such forward-looking statements, whether concerning the COVID-19 pandemic or otherwise, involve risks, assumptions and uncertainties. Except for historical information, statements about future volumes, sales, growth, costs, cost savings, margins, earnings, earnings per share, diluted earnings per share, cash flows, plans, objectives, expectations, growth or profitability are forward-looking statements based on management’s estimates, beliefs, assumptions and projections. Words such as “could,” “may,” “expects,” “anticipates,” “will,” “targets,” “goals,” “projects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “predicts,” and variations on such words, and similar expressions that reflect our current views with respect to future events and operational, economic and financial performance, are intended to identify such forward-looking statements. These forward-looking statements are only predictions, subject to risks and uncertainties, and actual results could differ materially from those discussed. Important factors that could affect performance and cause results to differ materially from management’s expectations, or could affect the company’s ability to achieve its strategic goals, include the uncertainties relating to the impact of COVID-19 on the company’s business, operations and employees and the other factors that are described in the sections entitled “Risk Factors” and “Management’s Discussion and Analysis” in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2019, as updated from time to time in the company’s Securities and Exchange Commission filings. The company’s forward-looking statements in this press release are based on management’s current views, beliefs, assumptions and expectations regarding future events and speak only as of the date of this release. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by the federal securities laws. CONTACT: Inquiries: investors@precipiodx.com +1-203-787-7888 Ext. 523
- GlobeNewswire
Precipio Signs HemeScreen™ Deals with Two Leading Oncology Groups
Partnership with ION Solutions expected to accelerate salesNEW HAVEN, Conn., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) has signed agreements with two of the largest oncology practices in the US, West Cancer Center of Memphis, TN; and New York Cancer & Blood Specialists of New York. During the coming weeks, both practices will be bringing Precipio’s HemeScreen technology in-house. The implementation of HemeScreen will enable these practices to significantly improve turnaround time for important molecular tests for diseases such as MPN (Myeloproliferative Neoplasms), CLL (Chronic Lymphocytic Leukemia) and AML (Acute Myeloid Leukemia), delivering better care to their cancer patients. Following the recent publication introducing HemeScreen to physician office laboratories (POLs) in ION’s Oncologists Magazine, the partnership with ION has the potential to continue to open doors to hundreds of independent community oncology practices nationwide, with a joint effort of both companies’ sales teams to introduce this patient-centric technology to those groups. The onboarding of these two customers will have a material impact to Precipio, and has the potential to generate seven-figure revenue to Precipio. As Precipio’s R&D team continues to expand its panels and its HemeScreen offering to new diseases, the company’s growing installed customer base will benefit from broadened testing opportunities, increasing revenue to the oncology practice. These ongoing developments will also have the potential of delivering increased market share and revenue to Precipio from expanded reagent sales. “As a patient-centric practice, we are constantly seeking innovative technologies to improve the way we care for our patients”, said Dr. Vacirca, CEO of New York Cancer & Blood Specialists. “HemeScreen will help us identify the patient’s molecular profile faster, so that we can deliver the best, most accurate and rapid care to our patients.” “The trust that these prominent practices have placed in Precipio is a testament to the value, both clinical and financial, of HemeScreen to the market; we are excited to continue and rapidly expand the market penetration of HemeScreen in the POL market”, said Ilan Danieli, Precipio’s CEO. “Consistent with our mission, we are delighted to play a role in continuing to help the diagnostic community provide better care and reduced diagnostic errors for their patients”. About Precipio Precipio has built a platform designed to eradicate the problem of misdiagnosis by harnessing the intellect, expertise and technology developed within academic institutions and delivering quality diagnostic information to physicians and their patients worldwide. Through its collaborations with world-class academic institutions specializing in cancer research, diagnostics and treatment such as the Yale School of Medicine, Harvard’s Dana-Farber Cancer Institute, and the University of Pennsylvania, Precipio offers a new standard of diagnostic accuracy enabling the highest level of patient care. For more information, please visit www.precipiodx.com. About HemeScreen™ Reagent Rental (HSRR) Program Precipio’s HemeScreen Reagent Rental Program for POLs applies its patent-pending HemeScreen™ technology beyond the laboratory and into the point of care setting, in the oncologist’s office. A tried-and-true structure that is prevalent in the diagnostic world, the HemeScreen Reagent Rental (HSRR) program enables office-based physicians to place Real-Time PCR (RT-PCR) testing equipment with no capital outlay and generate profitable revenue from day one. Through this program, the physician practice will have the ability to run the diagnostic tests in-house instead of sending out to reference laboratories, obtaining faster results and providing patients with better care. All panels and genes are reimbursed by Medicare and insurance companies. Customers make one monthly payment to purchase HemeScreen reagents, which will subsidize the cost of the PCR equipment and all necessary support, creating a profitable business model for the POLs. For more information please visit our website at http://www.precipiodx.com/hemescreen.html. Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, among others, statements related to the expected or potential impact of the novel coronavirus (COVID-19) pandemic, and the related responses of the government, consumers, and the company, on our business, financial condition and results of operations, and any such forward-looking statements, whether concerning the COVID-19 pandemic or otherwise, involve risks, assumptions and uncertainties. Except for historical information, statements about future volumes, sales, growth, costs, cost savings, margins, earnings, earnings per share, diluted earnings per share, cash flows, plans, objectives, expectations, growth or profitability are forward-looking statements based on management’s estimates, beliefs, assumptions and projections. Words such as “could,” “may,” “expects,” “anticipates,” “will,” “targets,” “goals,” “projects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “predicts,” and variations on such words, and similar expressions that reflect our current views with respect to future events and operational, economic and financial performance, are intended to identify such forward-looking statements. These forward-looking statements are only predictions, subject to risks and uncertainties, and actual results could differ materially from those discussed. Important factors that could affect performance and cause results to differ materially from management’s expectations, or could affect the company’s ability to achieve its strategic goals, include the uncertainties relating to the impact of COVID-19 on the company’s business, operations and employees and the other factors that are described in the sections entitled “Risk Factors” and “Management’s Discussion and Analysis” in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2019, as updated from time to time in the company’s Securities and Exchange Commission filings. The company’s forward-looking statements in this press release are based on management’s current views, beliefs, assumptions and expectations regarding future events and speak only as of the date of this release. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by the federal securities laws. CONTACT: Inquiries: investors@precipiodx.com +1-203-787-7888 Ext. 523
- GlobeNewswire
Precipio Signs Sales & Marketing Agreement for HemeScreen™ with Major Oncology Distributor
Thousands of Oncology Practices will gain access to HemeScreen POL programNEW HAVEN, Conn., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) has entered into an agreement with a major US-based oncology distributor to offer Precipio’s HemeScreen POL (Physician Office Lab) program to its independent community oncology practices nationwide. At this time, the company had requested to remain unnamed in this press release. Through its sales and distribution network, the distributor serves community oncologists nationwide. These practices face daily challenges competing with the large healthcare networks, and must constantly improve their ability to compete from a patient care standpoint, while ensuring their financial sustainability. The ability to deliver better patient care through rapid turnaround time; the internalization of testing which leads to better control; and the opportunity to generate profitable revenue by those practices, are all at the core of Precipio’s vision in creating this program to support community oncologists.Precipio estimates that an average practice participating in the Hemescreen POL program (depending on the practice size) could generate revenues for Precipio of $100,000 per year in HemeScreen reagent sales.Both companies will be collaborating to develop a joint program to offer the community oncology practices. The companies will join forces to introduce the program to these oncology practices, leveraging both sales forces; educating customers on the benefits, and work in concert to handle the sales, contracting, setup and training processes for these customers.“This is a partnership where both parties’ interests are perfectly aligned,” said Ilan Danieli, Precipio’s CEO. “The combination of a strong, broad network reaching thousands of oncologists within the community, coupled with Precipio’s technology platform, provides yet another anchor of support to this important pillar of the oncology community. We are excited for the teams to bring this program to the benefit of those customers”.HemeScreen Reagent Rental (HSRR) ProgramPrecipio’s HemeScreen Reagent Rental Program for POLs applies its patent-pending HemeScreen™ technology beyond the laboratory and into the point of care setting, in the oncologist’s office. A tried-and-true structure that is prevalent in the diagnostic world, the HemeScreen Reagent Rental (HSRR) program enables office-based physicians to place Real-Time PCR (RT-PCR) testing equipment with no capital outlay, and generate profitable revenue from day 1.Through this program, the physician practice will have the ability to run the diagnostic tests in-house instead of sending out to reference laboratories, obtaining faster results and providing patients with better care. Customers will make one monthly payment to purchase HemeScreen reagents, which will subsidize the cost of the PCR equipment.For more information please visit our website at http://www.precipiodx.com/hemescreen.html.About PrecipioPrecipio has built a platform designed to eradicate the problem of misdiagnosis by harnessing the intellect, expertise and technology developed within academic institutions and delivering quality diagnostic information to physicians and their patients worldwide. Through its collaborations with world-class academic institutions specializing in cancer research, diagnostics and treatment such as the Yale School of Medicine, Harvard’s Dana-Farber Cancer Institute, and the University of Pennsylvania, Precipio offers a new standard of diagnostic accuracy enabling the highest level of patient care. For more information, please visit www.precipiodx.com.Forward-Looking StatementsThis press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, among others, statements related to the expected or potential impact of the novel coronavirus (COVID-19) pandemic, and the related responses of the government, consumers, and the company, on our business, financial condition and results of operations, and any such forward-looking statements, whether concerning the COVID-19 pandemic or otherwise, involve risks, assumptions and uncertainties. Except for historical information, statements about future volumes, sales, growth, costs, cost savings, margins, earnings, earnings per share, diluted earnings per share, cash flows, plans, objectives, expectations, growth or profitability are forward-looking statements based on management’s estimates, beliefs, assumptions and projections. Words such as “could,” “may,” “expects,” “anticipates,” “will,” “targets,” “goals,” “projects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “predicts,” and variations on such words, and similar expressions that reflect our current views with respect to future events and operational, economic and financial performance, are intended to identify such forward-looking statements. These forward-looking statements are only predictions, subject to risks and uncertainties, and actual results could differ materially from those discussed. Important factors that could affect performance and cause results to differ materially from management’s expectations, or could affect the company’s ability to achieve its strategic goals, include the uncertainties relating to the impact of COVID-19 on the company’s business, operations and employees and the other factors that are described in the sections entitled “Risk Factors” and “Management’s Discussion and Analysis” in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2019, as updated from time to time in the company’s Securities and Exchange Commission filings.The company’s forward-looking statements in this press release are based on management’s current views, beliefs, assumptions and expectations regarding future events and speak only as of the date of this release. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by the federal securities laws. CONTACT: Inquiries: investors@precipiodx.com +1-203-787-7888 Ext. 523
